BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15458518)

  • 1. Prolonged course of pure red cell aplasia after erythropoietin therapy.
    Nigg L; Schanz U; Ambühl PM; Fehr J; Bachli EB
    Eur J Haematol; 2004 Nov; 73(5):376-9. PubMed ID: 15458518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pure red cell aplasia (PRCA) induced by anti-EPO antibodies: epidemiology, diagnosis and treatment].
    Janda K; Kraśniak A; Krzanowski M; Sułowicz W
    Przegl Lek; 2010; 67(3):187-91. PubMed ID: 20687383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of erythropoietin-associated pure red cell aplasia.
    Carson KR; Evens AM; Bennett CL; Luminari S
    Best Pract Res Clin Haematol; 2005; 18(3):467-72. PubMed ID: 15792921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
    Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options.
    Rossert J; Macdougall I; Casadevall N
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv23-26. PubMed ID: 15827054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?
    Macdougall IC
    Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii18-21. PubMed ID: 16079325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation.
    Praditpornsilpa K; Buranasot S; Bhokaisuwan N; Avihingsanon Y; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; Intarakumtornchai T; Tungsanga K
    Nephrol Dial Transplant; 2005 Mar; 20(3):626-30. PubMed ID: 15735244
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
    Opatrný K
    Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies.
    Yang J; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Lee JS
    J Nephrol; 2005; 18(1):102-5. PubMed ID: 15772931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
    Macdougall IC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv9-15. PubMed ID: 15827058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents].
    Rossert J; Casadevall N
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S283-6. PubMed ID: 17373271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic mechanisms of EPO-associated pure red cell aplasia.
    Schellekens H
    Best Pract Res Clin Haematol; 2005; 18(3):473-80. PubMed ID: 15792922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to recombinant human erythropoietin causing pure red cell aplasia.
    Prabhakar SS; Muhlfelder T
    Clin Nephrol; 1997 May; 47(5):331-5. PubMed ID: 9181281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.
    Shimizu H; Saitoh T; Ota F; Jimbo T; Tsukada Y; Murakami H; Nojima Y
    Acta Haematol; 2011; 126(2):114-8. PubMed ID: 21654161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pure red cell aplasia due to treatment with epoietin beta: first case report of PRCA from Poland.
    Sułowicz W; Bentkowski W; Stompór T; Gross J; Biłyk A; Rudzki Z
    Przegl Lek; 2006; 63(9):810-4. PubMed ID: 17479877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.
    Evens AM; Bennett CL; Luminari S
    Best Pract Res Clin Haematol; 2005; 18(3):481-9. PubMed ID: 15792923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pure red cell aplasia secondary to treatment with erythropoietin.
    Locatelli F; Del Vecchio L
    J Nephrol; 2003; 16(4):461-6. PubMed ID: 14696747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia.
    Summers S; Holdsworth S; Sharples E
    Nephrol Dial Transplant; 2008 Oct; 23(10):3053-5. PubMed ID: 18558625
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge.
    Smalling R; Foote M; Molineux G; Swanson SJ; Elliott S
    Biotechnol Annu Rev; 2004; 10():237-50. PubMed ID: 15504708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.